类风湿关节炎相关性肺间质病变治疗进展

doi:10.3969/j.issn.1004-583X.2021.01.016

摘要/Abstract

摘要：

类风湿关节炎相关肺间质病变(RA-ILD)是类风湿关节炎(RA)患者死亡的主要原因之一,然而目前RA-ILD并无确凿的治疗方案。近年来越来越多关于RA-ILD药物的研究,包括免疫抑制剂、传统改善病情抗风湿药物、改善病情抗风湿生物制剂、靶向合成改善病情抗风湿药及抗纤维化等药物。本文对近年来RA-ILD治疗进行综述。

关键词: 关节炎, 类风湿, 肺疾病, 间质性, 治疗

中图分类号:

R593.22

何欣, 黄玉琴, 青玉凤, 张全波. 类风湿关节炎相关性肺间质病变治疗进展[J]. 临床荟萃, 2021, 36(1): 75-79.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.01.016

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I1/75

参考文献 44

[1]	Shaw M, Bridget FC, Lawrence AH, et al. Rheumatoid arthritis-associated lung disease[J]. Eur Respir Rev, 2015,24(135):1-16. doi: 10.1183/09059180.00008014 URL
[2]	Bendstrup E, Møller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians[J]. J Clin Med, 2019,8(12):2038. doi: 10.3390/jcm8122038 URL
[3]	Brusselle G. Rheumatoid arthritis and interstitial lung disease[J]. Rheumatology (Oxford), 2010,49(8):1425-1426. doi: 10.1093/rheumatology/keq017 pmid: 20223815
[4]	Ciancio N, Pavone M, Torrisi SE, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases[J]. Multidiscip Respir Med, 2019,14:17. doi: 10.1186/s40248-019-0179-2 URL
[5]	Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers[J]. Am J Respir Crit Care Med, 2015,191(12):1403-1412. doi: 10.1164/rccm.201411-1950OC URL
[6]	England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease[J]. Curr Opin Rheumatol, 2020,32(3):255-263. doi: 10.1097/BOR.0000000000000703 pmid: 32141954
[7]	熊琴, 杨彦瑜, 谭敏, 等. 原发性干燥综合征相关肺间质病变治疗的研究进展[J]. 临床荟萃, 2019,34(10):948-952.
[8]	Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease[J]. Rheumatol, 2013,40(5):640-646. doi: 10.1093/rheumatology/40.6.640 URL
[9]	Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects[J]. Am J Med Sci, 2009,337(5):329-335. doi: 10.1097/MAJ.0b013e31818d094b pmid: 19295413
[10]	Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease[J]. Respir Med, 2016,121:117-122. doi: 10.1016/j.rmed.2016.11.007 URL
[11]	吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识小组. 吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识[J]. 中华风湿病学杂志, 2019,23(7):436-440.
[12]	Ota M, Iwasaki Y, Harada H, et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease[J]. Mod Rheumatol, 2017,27(1):22-28. doi: 10.3109/14397595.2016.1173816 URL
[13]	王春雨, 罗晓红. 改善病情抗风湿药与类风湿关节炎肺间质病变[J]. 中华风湿病学杂志, 2018,22(6):426-429.
[14]	Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update[J]. Ann Rheum Dis, 2014,7(3):492-509.
[15]	Tokano Y, Ogasawara H, Ando S, et al. Cyclosporin A therapy for interstitial pneumonitis associated with rheumatic disease[J]. Mod Rheumatol, 2002,12(4):305-310. doi: 10.3109/s101650200054 pmid: 24383997
[16]	Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report[J]. J Korean Med Sci, 2002,17(2):270-273. pmid: 11961317
[17]	Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis[J]. Rheumatology (Oxford), 2000,39(12):1422-1424. doi: 10.1093/rheumatology/39.12.1422 URL
[18]	Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus[J]. Res, 2018,23(11):1041-1048.
[19]	谢文慧, 张卓莉. Janus酪氨酸激酶抑制剂治疗类风湿关节炎的现状与展望[J]. 中华风湿病学杂志, 2019,23(7):482-486.
[20]	Sho S, Jun S, Hirotaka Y, et al. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice[J]. Arthritis Res Ther, 2019,21(1):184. doi: 10.1186/s13075-019-1963-2 URL
[21]	Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: Lights and shadows[J]. J Clin Med, 2020,9(4):1082. doi: 10.3390/jcm9041082 URL
[22]	Blandizzi C, Gionchetti P, Armuzzi A, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.[J]. Immunopathol Pharmacol, 2014,27:1-10.
[23]	Vassallo R, Matteson E, Thomas CJ. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition[J]. Chest, 2002,122(3):1093-1096. pmid: 12226061
[24]	Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis[J]. Eur Respir J, 2004,24(4):708. pmid: 15459153
[25]	Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease[J]. Clin Exp Rheumatol, 2007,25(1):23-28. pmid: 17417986
[26]	Huang Y, Lin W, Chen Z, et al. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?[J]. Drug Des Devel Ther, 2019,13:2111-2125. doi: 10.2147/DDDT URL
[27]	Schultz R, Mattila J, Gappa M, et al. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA)[J]. Pediatr Pulmonol, 2001,32(5):397-402. doi: 10.1002/ppul.1149 URL
[28]	Wang Y, Xu SQ, Xu JH, et al. Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease[J]. Clin Med Insights Case Rep, 2011,4:49-52.
[29]	Lindsay K, Melsom R, Jacob BK, et al. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment[J]. Rheumatology (Oxford), 2006,45(8):1048-1049. doi: 10.1093/rheumatology/kel090 URL
[30]	姜少杰, 梁仕睿, 张雪芹, 等. IL-6/IL-6受体轴及其靶向抑制剂研究进展[J]. 细胞与分子免疫学杂志, 2019,35(6):569-574.
[31]	杜勤, 徐红娣. 托珠单抗对类风湿关节炎患者疗效、免疫球蛋白及辅助性T细胞水平的影响[J]. 药学实践杂志, 2020,38(1):71-73, 87.
[32]	Manfredi A, Cassone G, Furini F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study[J]. Intern Med J, 2019 Oct 29.[Online ahead of print]
[33]	英国警示托珠单抗的罕见严重肝损伤风险[J]. 中国药物评价, 2019,36(6):434.
[34]	Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease[J]. Respirology, 2014,19(3):353-359. doi: 10.1111/resp.2014.19.issue-3 URL
[35]	Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre[J]. Rheumatology (Oxford), 2017,56(8):1348-1357. doi: 10.1093/rheumatology/kex072 URL
[36]	MacIsaac J, Siddiqui R, Jamula E, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin[J]. Transfusion, 2018,58(11):2729-2735. doi: 10.1111/trf.14841 pmid: 30244480
[37]	Blair HA, Deeks ED. Abatacept: A review in rheumatoid arthritis[J]. Drugs, 2017,77(11):1221-1233. doi: 10.1007/s40265-017-0775-4 URL
[38]	Yamada H, Tsuru T, Otsuka T, et al. Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production[J]. Immunol Med, 2020 Jan 29; 1-5.[Online ahead of print]
[39]	Jiménez-Alvarez L, Arreola JL, Ramírez-Martínez G, et al. The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis[J]. Exp Mol Pathol, 2011,91(3):718-722. doi: 10.1016/j.yexmp.2011.09.010 URL
[40]	Boleto G, Guignabert C, Pezet S, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis[J]. Arthritis Res Ther, 2018,20(1):197. doi: 10.1186/s13075-018-1694-9 URL
[41]	Fernández-Díaz C, Loricera J, Castañeda S, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients[J]. Semin Arthritis Rheum, 2018,48(1):22-27. doi: 10.1016/j.semarthrit.2017.12.012 URL
[42]	Cassone G, Manfredi A, Atzeni F, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: A multicenter retrospective study[J]. J Clin Med, 2020,9(1):277. doi: 10.3390/jcm9010277 URL
[43]	Kurata I, Tsuboi H, Terasaki M, et al. Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis[J]. Intern Med, 2019,58(12):1703-1712. doi: 10.2169/internalmedicine.2226-18 URL
[44]	Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation[J]. Heart Lung Transplant, 2015,34(1):1-15. doi: 10.1016/j.healun.2014.06.014 URL

类风湿关节炎相关性肺间质病变治疗进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	金鑫, 吴金玲, 尹丽丽. 持续性植物状态促醒机制及治疗研究进展[J]. 临床荟萃, 2024, 39(2): 172-176.
[3]	王沁濡, 尹琴, 李娟, 甘洪玉. 中医药治疗慢性阻塞性肺疾病合并肺动脉高压的研究进展[J]. 临床荟萃, 2024, 39(2): 188-192.
[4]	王琦, 陈宏. 维生素D在支气管哮喘和慢性阻塞性肺疾病治疗中的应用进展[J]. 临床荟萃, 2024, 39(1): 88-91.
[5]	张娜娜, 崔轶霞, 邹琳. 类风湿关节炎患者骨密度与维生素D相关性研究进展[J]. 临床荟萃, 2024, 39(1): 92-96.
[6]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[7]	邹子良, 余海, 王迪, 褚泰运, 李驹, 钱宝堂. 冠状动脉慢性完全闭塞病变介入治疗研究现状[J]. 临床荟萃, 2024, 39(1): 80-83.
[8]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[9]	王鑫, 张展, 刘铎, 谢萍. 铁缺乏与肺动脉高压相关性的研究进展[J]. 临床荟萃, 2023, 38(9): 838-844.
[10]	陈聪水, 李园, 陈淑芳. 重视儿童胆源性胰腺炎的中西医诊治(附1例分析)[J]. 临床荟萃, 2023, 38(8): 726-730.
[11]	武颖颖, 孔维香. 端粒及端粒酶逆转录酶基因与慢性阻塞性肺疾病相关性的研究进展[J]. 临床荟萃, 2023, 38(8): 749-752.
[12]	左腾, 王俊祥. 血清阴性类风湿关节炎发病机制的研究进展[J]. 临床荟萃, 2023, 38(8): 753-756.
[13]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[14]	侯有玲, 李奕, 关红玉, 罗红霞. 目标导向液体治疗在脑肿瘤切除术中应用效果的meta分析[J]. 临床荟萃, 2023, 38(8): 686-693.
[15]	王玥, 陈辉, 岑奕, 张哲, 张欣, 李宗锡, 陈珍珍, 贾彤彤, 章美玲. 超声引导下侧入路颈脊神经后支三氧联合注射松解治疗颈脊神经后支源性慢性颈肩痛[J]. 临床荟萃, 2023, 38(8): 714-718.